NASDAQ:MTVA MetaVia (MTVA) Stock Price, News & Analysis $1.60 -0.04 (-2.21%) As of 02/21/2025 03:48 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsTrends About MetaVia Stock (NASDAQ:MTVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MetaVia alerts:Sign Up Key Stats Today's Range$1.55▼$1.7050-Day Range$1.60▼$2.4952-Week Range$1.51▼$6.75Volume19,461 shsAverage Volume22,034 shsMarket Capitalization$13.82 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Read More… MetaVia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreMTVA MarketRank™: MetaVia scored higher than 33% of companies evaluated by MarketBeat, and ranked 778th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMetaVia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMetaVia has only been the subject of 1 research reports in the past 90 days.Read more about MetaVia's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MetaVia are expected to grow in the coming year, from ($3.90) to ($1.64) per share.Price to Book Value per Share RatioMetaVia has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MetaVia's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MTVA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetaVia does not currently pay a dividend.Dividend GrowthMetaVia does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MTVA. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows5 people have added MetaVia to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MetaVia insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.05% of the stock of MetaVia is held by insiders.Percentage Held by InstitutionsOnly 1.37% of the stock of MetaVia is held by institutions.Read more about MetaVia's insider trading history. Receive MTVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter. Email Address MTVA Stock News HeadlinesMetaVia Advances Therapeutics with Promising Trial UpdatesJanuary 10, 2025 | tipranks.comMetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 ConferenceJanuary 10, 2025 | prnewswire.comThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky, Tennessee and beyond… It's one of our country’s most scenic areas. But hidden beneath the beauty is an ugly reality: our most beautiful land is also the poorest. It’s a tragedy because for over 200 years, generation after generation has worked “coal country” with nothing but a pick and shovel, hauling billions of dollars from the ground.February 22, 2025 | Porter & Company (Ad)MetaVia initiated with a Buy at H.C. WainwrightDecember 31, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)December 31, 2024 | markets.businessinsider.comMTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…December 21, 2024 | msn.comMerck-Hansoh deal for oral GLP-1 hurts obesity drug developersDecember 18, 2024 | msn.comMetaVia Announces Positive Phase 2a Clinical Data For DA-1241 In Patients With Presumed MASHDecember 18, 2024 | markets.businessinsider.comSee More Headlines MTVA Stock Analysis - Frequently Asked Questions How have MTVA shares performed this year? MetaVia's stock was trading at $2.03 on January 1st, 2025. Since then, MTVA stock has decreased by 21.0% and is now trading at $1.6038. View the best growth stocks for 2025 here. How do I buy shares of MetaVia? Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today2/22/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTVA CUSIPN/A CIK1638287 Webwww.neurobopharma.com Phone857-702-9600Fax734-293-0444Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+648.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-189.12% Return on Assets-122.31% Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick Ratio2.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book0.47Miscellaneous Outstanding Shares8,616,000Free Float8,526,000Market Cap$13.82 million OptionableN/A Beta-0.22 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:MTVA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
